Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma.
Apoptosis : an international journal on programmed cell death, cilt.31, sa.2, ss.56, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 2
- Basım Tarihi: 2026
- Doi Numarası: 10.1007/s10495-026-02275-5
- Dergi Adı: Apoptosis : an international journal on programmed cell death
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
- Sayfa Sayıları: ss.56
- İstanbul Medipol Üniversitesi Adresli: Evet
Özet
Abstract
Glioblastoma is the most aggressive and most common grade 4 tumor of the central nervous system (CNS). Despite standard treatments such as surgical resection and chemoradiotherapy, overall survival (OS) usually does not exceed 14-16 months in clinical trials, and no improvement in OS has been demonstrated even with the use of vascular endothelial growth factor A (VEGFA) inhibitors such as bevacizumab. In response to radiotherapy, hypoxia-inducible factor (HIF) stabilization leads to activation of alternative pro-angiogenic pathways, increasing VEGF expression and tumor angiogenesis. Several clinical trials evaluating HIF-2α inhibitors as monotherapy in the absence of concurrent VEGF inhibition, have similarly failed to demonstrate a significant improvement in OS outcomes. This review provides a perspective on the combined use of VEGF and HIF inhibitors, and provides an insight into future studies.